HFpEF验前概率对毛细血管前肺动脉高压结局的临床意义
本研究基于多中心PVDOMICS研究中的424例第1组肺动脉高压患者,采用HFpEF-ABA算法评估HFpEF验前概率。结果显示,HFpEF概率越高,静息及激发后肺毛细血管楔压升高越明显,功能状态和生活质量越差,死亡风险越高。
要点
- HFpEF验前概率可识别第1组肺动脉高压中合并亚临床左心病的亚组。
- 高HFpEF概率患者动态肺毛细血管楔压反应更差,功能状态和生存更差。
- 该亚组需进一步研究肺动脉高压治疗及HFpEF特异性治疗的效果与安全性。
核心结论
- 在第1组肺动脉高压患者中,量化HFpEF验前概率可识别出动态肺毛细血管楔压反应更差、功能状态和生活质量更差、生存更差的亚组。
研究设计与样本
- 基于多中心PVDOMICS研究,纳入424例第1组肺动脉高压患者,使用HFpEF-ABA算法(基于年龄、体重指数和房颤病史)评估HFpEF验前概率。
主要发现
- 424例第1组肺动脉高压患者中,54%(n=228)为中等HFpEF概率,15%(n=64)为高HFpEF概率。
- 静息肺毛细血管楔压随HFpEF概率升高而逐渐增加(P < 0.0001)。
- 高HFpEF概率患者在一氧化氮、液体负荷和运动激发后肺毛细血管楔压升高幅度最大(所有P < 0.001)。
- 高HFpEF概率患者的左室/左房大小、舒张功能、生活质量、6分钟步行距离和峰值VO2最异常(所有P < 0.0001)。
- 第1组肺动脉高压中HFpEF概率增加与死亡风险升高相关(HFpEF概率每增加十分位HR 1.09;95%CI:1.05-1.13;P < 0.0001)。
关键数值与推荐
- HFpEF验前概率分层:低(<25%)、中等(25%-74%)、高(≥75%)ABA评分。
临床怎么用
- 对第1组肺动脉高压患者可计算HFpEF-ABA验前概率,高概率者提示亚临床左心病,需关注动态肺毛细血管楔压反应及预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with group 1 pulmonary hypertension (PH) and risk factors for heart failure with preserved ejection fraction (HFpEF) demonstrate worse response to pulmonary vasodilator therapy. The mechanisms and optimal diagnostic approach to identify such patients remain unclear. OBJECTIVES: The purpose of this study was to compare exercise capacity, cardiac function, and hemodynamic responses to provocative maneuvers among patients with group 1 PH based upon pretest probability of HFpEF. METHODS: Pretest probability for HFpEF was determined using the validated HFpEF-ABA algorithm based on age, body mass index, and history of atrial fibrillation among group 1 PH patients recruited to the multicenter PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) study. Functional capacity, quality of life, and dynamic pulmonary capillary wedge pressure (PCWP) responses were compared between those with low (<25%), intermediate (25%-74%), and high (≥75%) ABA score-based HFpEF probability. RESULTS: Among 424 patients with group 1 PH, 54% (n = 228) had intermediate HFpEF probability and 15% (n = 64) had high HFpEF probability. Resting PCWP increased progressively with higher HFpEF probability (P < 0.0001), and patients with group 1 PH and high HFpEF probability had the greatest increases in PCWP with nitric oxide, fluid challenge, and exercise (P < 0.001 for all), changes that were comparable to patients with HFpEF with no pulmonary vascular disease (n = 194), but lower than those with HFpEF and combined precapillary and postcapillary PH. Left ventricular/atrial size, diastolic function, quality of life, 6-minute walk distance, and peak VO2 were most abnormal in patients with group 1 PH and high HFpEF probability compared with those with low or intermediate HFpEF probability (P < 0.0001 for all). Increasing HFpEF probability in group 1 PH was associated with greater risk of death (HR per decile of HFpEF probability 1.09; 95% CI: 1.05-1.13; P < 0.0001). CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with group 1 PH identifies a subset of patients with worse dynamic PCWP response indicative of subclinical left heart disease, with poorer functional status, quality of life, and survival. Further study in this group 1 PH subgroup is indicated to determine whether PH therapies are effective and safe, and also whether HFpEF-specific therapies can improve functional status and outcomes.
引用
- Reddy YNV, Frantz RP, Hassoun PM, et al. Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension. J Am Coll Cardiol. 2024. PMID: 39453363. doi:10.1016/j.jacc.2024.08.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。